Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AbundRX vs Blue Sky MD

AbundRX
Graded #193

Lower grade

vs+1.2000000000000028
Blue Sky MD
Graded #169

Higher grade

The verdict

Blue Sky MD takes it — 67.5/100 to 66.3/100, but only just.

Blue Sky MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Blue Sky MD is a LegitScript-certified medical weight-loss practice founded in 2008 with seven North Carolina clinics and telehealth visits available. AbundRX is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAbundRX +2
66
64
Dose & formulationEven
64
64
Clinical oversightBlue Sky MD +8
79
87
Labs & monitoringBlue Sky MD +9
53
62
FulfillmentAbundRX +11
74
63
Contract termsEven
55
55
AbundRX · left barBlue Sky MD · right bar

The numbers

MetricAbundRXBlue Sky MD
WeighScore66.3/10067.5/100
GradeCC
Scorecard rank#193#169
Semaglutide$179/mo (compounded)$160/mo (starting dose, compounded)
Tirzepatide$279/mo (compounded)$240/mo (starting dose, compounded)
CoverageCoverage not published1 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
AbundRX

Graded #193 · C

Strengths

  • Two clear compounded GLP-1 pathways with transparent pricing — semaglutide $179/mo and tirzepatide $279/mo
  • Fast, free shipping and a simple few-minute online health assessment
  • Provider-guided care connecting patients with licensed US clinicians
  • Publishes Terms, Privacy, and Refund policies

Where it loses points

  • Claims LegitScript certification in text but displays no verifiable seal or listing
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Compounding pharmacy not named; no HIPAA notice found; state availability not published
  • Heavily hedged marketing language ('may include', 'helping connect patients') — reads like a lead-generation platform
Blue Sky MD

Graded #169 · C

Strengths

  • LegitScript certified and physician-led since 2008; one of the most established GLP-1 practices in the Southeast
  • Compounded semaglutide from $40/week (~$160/month) and tirzepatide from $60/week (~$240/month) — well below brand-name cost
  • Comprehensive program includes 1-on-1 wellness coaching, nutrition plans, hormone analysis, and a proprietary mobile app
  • Medication shipped directly to patients’ homes within 3–5 business days; telehealth visits available
  • Insurance accepted in many cases; affordable self-pay options for uninsured patients

Where it loses points

  • Geographic reach unclear — physical clinics in NC only; telehealth states beyond NC unconfirmed despite 'from virtually anywhere' claim
  • Pricing quoted per-week ($40 sema / $60 tirz) rather than per-month; higher-dose pricing not disclosed
  • Must enroll in full medical weight-loss program to access GLP-1 medications — medication-only Rx not offered
  • No explicit lab testing protocol published; online FAQ does not confirm labs are included
  • Small regional provider vs. national platforms; limited provider footprint outside North Carolina

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard